ArticleBioengineering (Basel, Switzerland)2025
NeuroNet-AD: A Multimodal Deep Learning Framework for Multiclass Alzheimer's Disease Diagnosis.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- ADGPT: A Prior-Guided and GPT-Empowered Framework for MRI-Based Alzheimer's Disease Diagnosis.Journal of imaging informatics in medicine · 2026Article
- Biomarker-Conditioned Vision Transformers with Deformable Biomarker Attention for Alzheimer's Disease Classification.Journal of imaging informatics in medicine · 2026Article
- Enhancing Alzheimer's disease classification with a transformer-based model using self-supervised learning.Scientific reports · 2026Article
- TriFusion-ADFormer: a deep learning framework for early Alzheimer's disease detection using MRI and cognitive metrics.Frontiers in artificial intelligence · 2026Article
- An interpretable multimodal ensemble assessment framework for Alzheimer's disease cognitive staging.Frontiers in neurology · 2026Article
- Integrating anatomical priors and clinical semantics for MRI-based diagnosis and care support in Alzheimer's disease.Frontiers in neuroscience · 2026Article
- Detection and Classification of Alzheimer's Disease Using Deep and Machine Learning.Tomography (Ann Arbor, Mich.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most prevalent form of dementia. This disease significantly impacts cognitive functions and daily activities. Early and accurate diagnosis of AD, including the preliminary stage of mild cognitive impairment (MCI), is critical for effective patient care and treatment development. Although advancements in deep learning (DL) and machine learning (ML) models improve diagnostic precision, the lack of large datasets limits further enhancements, necessitating the use of complementary data. Existing convolutional neural networks (CNNs) effectively process visual features but struggle to fuse multimodal data effectively for AD diagnosis. To address these challenges, we propose NeuroNet-AD, a novel multimodal CNN framework designed to enhance AD classifcation accuracy. NeuroNet-AD integrates Magnetic Resonance Imaging (MRI) images with clinical text-based metadata, including psychological test scores, demographic information, and genetic biomarkers. In NeuroNet-AD, we incorporate Convolutional Block Attention Modules (CBAMs) within the ResNet-18 backbone, enabling the model to focus on the most informative spatial and channel-wise features. We introduce an attention computation and multimodal fusion module, named Meta Guided Cross Attention (MGCA), which facilitates effective cross-modal alignment between images and meta-features through a multi-head attention mechanism. Additionally, we employ an ensemble-based feature selection strategy to identify the most discriminative features from the textual data, improving model generalization and performance. We evaluate NeuroNet-AD on the Alzheimer's Disease Neuroimaging Initiative (ADNI1) dataset using subject-level 5-fold cross-validation and a held-out test set to ensure robustness. NeuroNet-AD achieved 98.68% accuracy in multiclass classification of normal control (NC), MCI, and AD and 99.13% accuracy in the binary setting (NC vs. AD) on the ADNI dataset, outperforming state-of-the-art models. External validation on the OASIS-3 dataset further confirmed the model's generalization ability, achieving 94.10% accuracy in the multiclass setting and 98.67% accuracy in the binary setting, despite variations in demographics and acquisition protocols. Further extensive evaluation studies demonstrate the effectiveness of each component of NeuroNet-AD in improving the performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.